The interaction of the diltiazem with oral and intravenous cyclosporine in rats

European Journal of Drug Metabolism and Pharmacokinetics
Sule KalkanHulya Guven

Abstract

This study investigated the effect of diltiazem on the bioavailability of oral and intravenous cyclosporine (CsA) in rats. While control rats received normal saline, experimental groups received 60 or 90 mg/kg diltiazem orally for 3 days. Each group divided into 2 equal groups that received a single oral dose or i.v. injection of CsA. Pharmacokinetic parameters were analyzed by nonparametric analysis of variance. Pretreatment with 60 or 90 mg/kg diltiazem decreased the area under the blood CsA concentration-time curve (AUC) of oral CsA compared to control group (54.5% and 65.5% for AUC(0-24), 57.6% and 62.2% for AUC(0-infinity), respectively, p<0.05). Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05). The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%). Pretreatment with 90 mg/kg but not 60 mg/kg of diltiazem increased the AUC(0-infinity), elimination half-life (t1/2) of intravenous CsA (116.0%, 219.2%, respectively, p<0.05) and decreased the intravenous CsA clearence (CL(i.v.)) (62.9%, p<0.05). Diltiazem decreased...Continue Reading

References

Nov 1, 1992·The Journal of Clinical Investigation·J C KolarsP B Watkins
Feb 1, 1991·The Journal of Pharmacy and Pharmacology·A M BrittonP R Draper
Dec 14, 1991·Lancet·J C KolarsP B Watkins
Jan 1, 1991·Nephron·F MartinezC van Ypersele de Strihou
Feb 1, 1991·Journal of Pharmacokinetics and Biopharmaceutics·A Bernareggi, M Rowland
Oct 1, 1990·Clinical Pharmacokinetics·G C Yee, T R McGuire
Nov 1, 1990·Clinical Pharmacokinetics·G C Yee, T R McGuire
Jan 1, 1989·European Journal of Clinical Pharmacology·M KesslerB Dousset
May 1, 1989·Pharmacology & Toxicology·J MäenpääO Pelkonen
Sep 1, 1988·Drug Intelligence & Clinical Pharmacy·T G Maggio, D W Bartels
Mar 1, 1986·Clinical Pharmacokinetics·R J PtachcinskiG J Burckart
Feb 1, 1987·Transplantation·N K WadhwaM R First
Dec 1, 1986·British Journal of Pharmacology·R BrageC Rodriguez
Apr 1, 1984·Biopharmaceutics & Drug Disposition·C T UedaK Nussbaumer
Sep 7, 1995·The New England Journal of Medicine·A KeoghA Kaan
Jun 1, 1995·The Annals of Pharmacotherapy·R L Slaughter, D J Edwards
Jan 1, 1994·Biopharmaceutics & Drug Disposition·A Lindberg-Freijs, M O Karlsson
May 1, 1996·Biological & Pharmaceutical Bulletin·M OhbaK Okumura
Feb 12, 1998·British Journal of Clinical Pharmacology·T E JonesT H Mathew
Jul 29, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·M SpoendlinG Thiel
Mar 17, 1999·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·R D WhalenR Venkataramanan

❮ Previous
Next ❯

Citations

Sep 16, 2014·Angewandte Chemie·Daniel S NielsenDavid P Fairlie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.